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A new amphiphilic GdDOTA-like complex functionalized with two 
octadecyl chains was synthesised and incorporated into the 
bilayer of liposomes and dendrimersomes. 
1
H NMR relaxometric 
studies and in vivo MRI experiments on mice bearing a syngeneic 
melanoma tumour have shown a great improvement in 
performance. 
In the last few years, nanomedicine has tremendously grown due to 
the great progresses achieved in the fields of nanotechnology, 
pharmacology, and molecular imaging.1,2 The versatility of 
nanosystems allows tuneable surface modification and loading with 
different chemicals (drugs, imaging agents, targeting vectors) with 
the aim of fine-optimizing the biological properties of the 
nanocarriers, while simultaneously enabling them to perform 
diagnostically and/or therapeutically important functions.3,4  
Lipid-containing nanoparticles (LNPs),5 like micelles, liposomes, and 
solid lipid nanoparticles, or other similar nanosystems (such as the 
recently developed dendrimersomes)6-8 are based on 
supramolecular aggregates obtained by spontaneous assembling in 
aqueous solution of phospholipids alone or in mixture with other 
amphiphilic molecules. Such objects have been frequently used as 
nanocarriers for drug delivery and imaging applications due to their 
great chemical versatility that allows the loading of hydrophobic, 
amphiphilic, and hydrophilic substances, and surface decoration 
with targeting vectors, blood lifetime modulators, and diagnostic 
agents.7-9 Moreover, several liposomal drug formulations have 
already been clinically approved for cancer treatment thanks to 
their ability to passively accumulate in the tumour tissue.10,11 
As far as theranostics is concerned, the use of nanoparticles can be 
also favourable for increasing the detection threshold of the 
imaging agent.12 This is particularly relevant for MRI, where the 
relatively low sensitivity of the technique can be overcome by 
delivering a high number of paramagnetic Gd(III) complexes at the 
biological target.13 Furthermore, the incorporation of an 
amphiphilic agent in the particle membrane can substantially 
improve its longitudinal relaxivity r1 (in the magnetic field range 0.5 
– 3 T) due to the restriction of the tumbling motion of the 
agent.14,15 So far, the most used amphiphilic Gd-agents have been: 
i) Gd-DTPA-bisamide derivatives bearing long aliphatic chains (e.g. 
Gd-DTPA-BSA)16,17, ii) a Gd-DOTA monoamide conjugated to two 
octadecyl tails (GdDOTAMA(C18)2),
16,18 and iii) a Gd-DOTA-
monoamide conjugated to the polar head of a phospholipid (1,2-
distearoyl-sn-glycero-3-phospho ethanolamine, DSPE) through a 
short C2 spacer.19 With respect to DTPA-bisamides, the two 
macrocyclic systems offer the advantage of much higher 
thermodynamic and kinetic stabilities, as well as higher relaxivities. 
The proton relaxivity of a discrete incorporated complex is often 
quite modest, typically 10–20 mM–1s–1 (25 °C, 0.5 T), much less than 
the highest values predicted by theory. The two major limiting 
factors are the slow water exchange rate (kex = 1/τM) of the inner 
sphere water molecule coordinated to the metal centre and/or the 
short local rotational correlation time (τRL) of the complex loaded 
on the nanoparticle. We have recently addressed the problem of 
the simultaneous optimization of kex and τRL using a GdDOTA-like 
complex (GdDOTA(GAC12)2) functionalized with two hydrophobic 
chains on adjacent pendant arms that serve to rigidify the 
incorporated chelate.20 The high relaxivity found in liposomes 
loaded with this complex was also confirmed in vivo at 1 T on a 
melanoma tumour model in mice.21 Remarkably, the Gd-probe is 
rapidly cleared from the organs due to the presence of the two 
dodecyl chains. Although a rapid excretion of the agent is in many 
cases favourable, in other applications it is preferable that the 
complex remains embedded in the nanoparticle for longer times. 
This condition is typically achieved using amphiphiles containing 
two palmitoyl/stearyl chains. 
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Scheme 1. Chemical structures of the amphiphilic Gd-chelates and 
of the Janus Dendrimer used for assembling dendrimersomes. 
 
With the aim of combining the excellent incorporation stability of 
GdDOTAMA(C18)2 into bilayered nanovesicles (liposomes, 
polymersomes, dendrimersomes)7,22 with the high relaxivity offered 
by the tetra-carboxylic cage of GdDOTA(GAC12)2, we synthesized the 
new amphiphilic chelate GdDOTAGA(C18)2 (Scheme 1).  
The motivation of this study was to investigate, either in vitro or in 
vivo, the imaging performance of nanovesicles (liposomes and 
dendrimersomes) loaded with GdDOTAGA(C18)2, and make a 
comparison with the corresponding nanoparticles embedded with 
GdDOTAMA(C18)2.  
The synthesis of GdDOTAGA(C18)2 was accomplished in four steps 
starting from DOTAGA(tBu)4 (Scheme S1): the free carboxylic acid 
was activated by formation of the N-hydroxysuccinimidyl ester, 
which was then reacted with dioctadecylamine in pyridine at 70°C. 
The free ligand was obtained after tBu esters deprotection using a 
1:1 mixture of TFA and dichloromethane and the Gd(III) complex 
was prepared by reacting the ligand with GdCl3 in methanol at 50°C 
overnight. Liposomes and dendrimersomes (DSs) were prepared 
using the conventional film hydration method7,23 (see ESI for 
details). DSs were formulated with the following moles percentage: 
20% of the amphiphilic Gd-complex, 75% of a recently reported low 
generation Janus Dendrimer (JDG0G1(3,5), Scheme 1),8 and 5% of 
DSPE-PEG2000-COOH. The pegylated phospholipid was used to 
improve particles stability and to confer stealthiness towards 
immune system.7,8 Liposomes were formulated using the same 
composition, except for the presence of 75 % of DPPC instead of the 
dendrimer. 
The magnetic field dependence of the relaxivity of the 
paramagnetic nanovesicles, the so-called nuclear magnetic 
relaxation dispersion (NMRD) profile, was measured at 25°C and 
37°C, over the range 2.343×10-4–1.645 T, which corresponds to 
proton Larmor frequencies varying from 0.01 to 70 MHz. The 
experimental profiles are reported in Figure 1 and S1 and show a 
peak centred around 30-40 MHz, which is characteristic of slowly 
tumbling systems.14,15 A statistically higher relaxivity was measured 
for the nanovesicles (both liposomes and dendrimersomes) loaded 
with GdDOTAGA(C18)2 with respect to the corresponding systems 
incorporating GdDOTAMA(C18)2, whereas no relevant differences 
were observed between liposomes and dendrimersomes. The 
NMRD profiles were fitted using the conventional paramagnetic 
relaxation model (based on Solomon-Bloembergen-Morgan and 
Freed’s theories)14 implemented by the Lipari-Szabo approach,24 
which is used to describe the rotational dynamics when the (fast) 
rotation of the coordination cage of the complex (τRL) partially 
couples to the slow tumbling of the whole nanoparticle (τRG). 
Assuming that the τM value of the incorporated GdDOTAGA(C18)2 is 
identical to that reported for the water soluble precursor 
GdDOTAGA,20 the large  

















Proton Larmor Frequency / MHz  

















Proton Larmor Frequency / MHz  
Figure 1.
 1H NMRD profiles at 298 K of paramagnetic 
dendrimerosomes (left) and liposomes (right) incorporating 
GdDOTAGA(C18)2 (● and ■) and GdDOTAMA(C18)2 (□ and ○). 
 
 
Table 1. Relaxation parameters (at 25°C) obtained from the analysis 
of the NMRD profiles.[a,b] 
 
 [a] The parameters for electronic relaxation were used as empirical fitting 
parameters and have no real physical meaning for nanosized systems. Hence, the 
data at magnetic field < 3 MHz, which are the most affected by electronic 
relaxation, were not included in data analysis, in accordance with a well-
established approach. For liposomes and dendrimersomes incorporating 
GdDOTAGA(C18)2 ∆
2 has a value of (1.4 ± 0.1) and (1.1 ± 0.1)×1019 s-2 and τV of 
(14.3 ± 0.8) and (14.5 ± 0.2) ps, respectively.  These values are comparable to 
those found for similar systems.20,21 [b] The distance of the coordinated water 
molecule from the metal ion (rGd-H) was fixed to 3.0 Å. The outer-sphere 
component of the relaxivity was estimated by using standard values for the 
distance of closest approach, a (4 Å) and the relative diffusion coefficient of 
solute and solvent, D (2.24×10-5 cm2 s-1). [c] Ref. 20; [d] Ref. 21; [c] Ref. 7. 
 
difference in the relaxivities of the two amphiphilic complexes in 
both nanovesicles can be mainly attributed to the different water 
exchange rates (Table 1). In fact, since the dioctadecyl moiety is 
connected similarly to both Gd-complexes, the τRL values and the 
order parameter S2 (indicating the coupling between local and 
global motions) did not differ substantially for the two complexes, 
thus showing a similar degree of rotational flexibility. The r1 values 
(30 MHz) of the complexes embedded in nanovesicles are shown in 
Figure 2. The plot highlights the remarkable relaxivity gain obtained 
by using GdDOTAGA(C18)2. A similar r1 value (40.0 mM
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τRG
298 (ns) 80 ± 5 82 80 ± 5 80 
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298 (ns) 1.96 ± 0.07 0.44 1.83 ± 0.05 0.55 
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Figure 2. Relaxivity values of the paramagnetic nanovesicles at 30 
MHz and 25 °C (left) and 37 °C (right) with highlighted the relaxivity 
gain obtained for the nanosystems incorporating GdDOTAGA(C18)2.   
 
obtained for liposomes incorporating GdDOTA(GAC12)2.
20,21 
Noteworthy, the greatest change in relaxivity is observed for 
liposomes at 37°C where the enhancement of r1 of GdDOTAGA(C18)2 
over the value observed for GdDOTAMA(C18)2 is as large as +379%. 
The temperature dependence of r1 is different for the two 
paramagnetic nanovesicles. By increasing temperature, the 
relaxivity of dendrimersomes slightly decreases for the vesicles 
embedding GdDOTAGA(C18)2 and increases for those incorporating 
GdDOTAMA(C18)2. This behaviour is a consequence of the different 
τM of the complexes that influences in a different manner the 
relaxivities. In the case of GdDOTAGA(C18)2, r1 is limited by the 
tumbling motion, thus by increasing the temperature the molecular 
rotation accelerates and r1 decreases. On the other hand, for 
GdDOTAMA(C18)2, r1 is limited by kex, and the increase of the 
temperature is accompanied by an increase of r1. However, in 
liposomes, a r1 enhancement occurred also for GdDOTAGA(C18)2. 
Likely, this observation reflects the lower water permeability of the 
liposome bilayer with respect to that of dendrimersomes.7 
Consequently, the contribution to the relaxivity arising from the 
complexes facing inward the liposomes cavity can be limited by the 
water diffusion across the membrane. Since this process is 
proportional to the temperature, the overall relaxivity at 37°C is 
higher than at 25°C.  
Since no side effects of cytotoxicity (Figure S2) were observed on 
cells after the exposure to dendrimersomes incorporating Gd-
DOTAGA(C18)2 (referred to as GdDOTAGA(C18)2-DS), the in vivo MRI 
performance of these nanoprobes was investigated on an 
experimental tumour model on a scanner operating at 1 T (40 
MHz), and the results were compared to analogous 










Figure 3. Representative axial T1w images of the tumour (white 
arrows) immediately before or 10 min after the administration of 
GdDOTAGA(C18)2 or GdDOTAMA(C18)2-loaded dendrimersomes. 
 
(GdDOTAMA(C18)2-DS). Suspensions of the paramagnetic vesicles 
were systemically administered via tail vein to mice bearing 
subcutaneous syngeneic B16 melanoma (0.05 mmol Gd kg-1 body 
weight) and T1-weighted images were acquired at different time 
points within two weeks to monitor the evolution of the T1 Contrast 
Enhancement (T1-CE) calculated as percentage in selected organs 
(liver, spleen, kidneys and tumour, Figure S3).  
Within 2 hours after the injection, all the examined organs showed 
a general brightening for both the paramagnetic nanovesicles due 
to their circulation in blood (Figure 3, 4, S4 and S5). Nevertheless, 
the T1-CE in all examined organs resulted to be significantly higher 
in animals receiving Gd-DOTAGA(C18)2-DS. Several hours after the 
administration, the T1-CE decreased in kidneys (both in renal cortex 
and pelvis), likely as a results of the clearance process and of the 
descending phase of the systemic circulation (Figure S4).  
On the contrary, the T1-CE in the organs devoted to the removal of 
the nanoparticles (i.e. liver and spleen) maintained stable for many 
days, preserving the difference initially calculated between the two 
cohorts of animals (Figure 4). Interestingly, after 24 h, the T1-CE in 
liver increased with respect to the post-injection values, possibly 
reflecting the dynamics of the particle deposition in this tissue, 
which is controlled by the cellular effectors of the reticulo-
endothelial system and may require a certain time to occur. 
Compared to the reference GdDOTAMA(C18)2-DS, GdDOTAGA(C18)2-
DS showed a 2-3 fold increase in T1-CE over the entire time window 
investigated. Gd3+ quantification by ICP-MS on the various 
explanted organs revealed an equivalent biodistribution pattern for 
the two employed nanosystems (Figure S6), thus confirming that 
the differences observed in the T1-CE actually reflected the different 












Figure 4. Time evolution of the percentage T1 Contrast Enhancement (T1-CE) calculated on T1-weighted images of tumor, liver and spleen 
of mice systemically injected with GdDOTAGA(C18)2 or GdDOTAMA(C18)2-loaded dendrimersomes (black squares and white squares, 
respectively). 
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However, both imaging and biodistribution profiles indicate a long-
term in vivo retention of the nanoprobes, which could possibly 
entail some safety risks in real biological use.  
In conclusion, we have reported the first in vivo MRI application of 
paramagnetic dendrimersomes incorporating a new, highly 
efficient, amphiphilic Gd-complex. The several favourable 
properties of this GdDOTA-like chelate, namely the high 
thermodynamic stability and kinetic inertness provided by the 
DOTA cage, the fast kex, the fairly easy preparation, and the 
improved relaxivity of the resulting lipid nanoparticles embedding  
the chelate, are expected to favour its widespread use in MRI and 
theranostic applications. We also confirmed that dendrimersomes 
might represent a valuable alternative to the use of liposomes, and 
can be appealing agents for the development of improved in vivo 
diagnostic and theranostic protocols. 
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